Evidence map›Paper›PMID 38349171›Full record

ArticlemSystems2024

Use of a combined antibacterial synergy approach and the ANNOgesic tool to identify novel targets within the gene networks of multidrug-resistant

Hyunsook Lee, Sung-Huan Yu, Jung Eun Shim, Dongeun Yong

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Hyunsook Lee *Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0002-0179-9999
Sung-Huan Yu *Institute of Precision Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
Jung Eun ShimBioinformatics Collaboration Unit, Yonsei Biomedical Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
Dongeun YongDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, South Korea.ORCID 0000-0002-1225-8477
Yonsei University · KRNational Sun Yat-sen University · TW

Funding

Brain Korea 21 PLUS Project for Medical Science, Yonsei UniversityHealth Fellowship Foundation 2022National Science and Technology Council (NSTC) MOST110-2222-E-110-008-MY3
6 · The paper itself

Abstract

Since the 1980s, the development of new drug classes for the treatment of multidrug-resistant

Indexed as

Klebsiella pneumoniaeRiboswitchAnimalsAnti-Bacterial AgentsColistinGene Regulatory NetworksHumansAnti-Bacterial AgentsColistinRiboswitchANNOgesicchemical compoundcolistingene networkmeropenemmultidrug-resistant (MDR)noncoding RNARNA sequencingsynergy

Identifiers

PMID38349171
PMCPMC10949472
OpenAlexW4391786294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.